Intuitive Surgical (NASDAQ:ISRG) Posts Quarterly Earnings Results, Beats Expectations By $0.35 EPS

Intuitive Surgical (NASDAQ:ISRG) issued its earnings results on Tuesday. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.35, FiscalAI reports. The firm had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.

Intuitive Surgical Stock Performance

ISRG stock traded up $4.82 during midday trading on Tuesday, reaching $438.00. 2,876,398 shares of the company traded hands, compared to its average volume of 2,407,321. The firm has a market capitalization of $154.74 billion, a price-to-earnings ratio of 50.17, a P/E/G ratio of 3.22 and a beta of 1.46. Intuitive Surgical has a 52-week low of $328.57 and a 52-week high of $603.88. The business has a 50 day moving average of $392.22 and a 200-day moving average of $409.24.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ISRG shares. Mizuho set a $415.00 price target on Intuitive Surgical in a research note on Tuesday, October 13th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Raymond James Financial reaffirmed an “outperform” rating and issued a $483.00 price objective (down from $577.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. Oppenheimer raised Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price objective on the stock in a report on Wednesday, August 12th. Finally, Barclays upgraded Intuitive Surgical to a “strong-buy” rating in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $498.83.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Strong robotic-surgery demand: Analysts point to rising procedure volumes, da Vinci 5 adoption and recurring revenue from instruments, accessories and service. Intuitive placed 246 da Vinci 5 systems in the second quarter, compared with 180 a year earlier, while procedures increased approximately 15%. 3 Wall Street Analysts See Intuitive Surgical Hitting $500
• Positive Sentiment: Analyst support: TD Cowen maintained a Buy rating and a $485 price target, citing robust robotic demand and potential upside if forecasts prove conservative. Several analysts see a path toward $500 as the installed base and procedure volumes expand. Intuitive Surgical Analyst Maintains Buy
• Positive Sentiment: Lower-cost adoption strategy: Intuitive plans to extend the useful life of surgical instruments beginning in 2027. Although this may reduce revenue per procedure initially, lower operating costs could make robotic surgery more attractive to hospitals and broaden long-term adoption. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
• Neutral Sentiment: Earnings are the immediate catalyst: Intuitive Surgical is scheduled to report after the market close. Investors are looking for procedure growth, da Vinci 5 placements, operating margins and management’s outlook. Revenue growth is expected to moderate to 15.6% year over year from 22.9% in the comparable quarter last year. Intuitive Surgical Q3 2026 Earnings Preview
• Negative Sentiment: Leasing raises capital-intensity concerns: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it requires Intuitive to fund equipment before realizing its lifetime returns. The stock’s elevated valuation also leaves less room for an earnings or guidance miss. Does Leasing Make Growth More Durable or More Capital Intensive?

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the transaction, the executive vice president owned 5,320 shares in the company, valued at $2,016,280. The trade was a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89. Following the completion of the sale, the executive vice president owned 881 shares of the company’s stock, valued at $330,877.17. This trade represents a 8.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 12,370 shares of company stock worth $4,891,989. 0.60% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.